Bubs Australia (BUB) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
20 Nov, 2025Opening remarks and agenda
Welcomed shareholders, auditors from KPMG, and share registry representatives; confirmed proper notice and opened the poll for voting.
Outlined voting procedures and confirmed eligibility; results to be released to the ASX and company website.
Acknowledgement of Country and respect paid to Traditional Custodians and Elders.
Board and executive committee updates
Paul Jensen became Chair after Katrina Rathie's resignation and offered himself for re-election.
Acknowledged contributions of outgoing Chair and CEO; highlighted board and committee roles.
Welcomed new CEO Joe Coote, emphasizing his international experience and leadership.
Chair and CEO delivered addresses outlining achievements, challenges, and future direction.
New CEO highlighted strong foundations, brand equity, and opportunities for commercial focus and innovation.
Financial performance review
Achieved annual revenue of AUD 103 million, 23% growth, 48% gross margin, and positive operating cash flow of AUD 6.1 million.
Underlying profit was AUD 600,000; statutory EBITDA was AUD 5.5 million, with adjustments for one-off items.
81% of sales from offshore markets; U.S. contributed 52%, China 21%, Australia 19%, rest of world 8%.
Inventory management improved, with inventory as a percentage of net revenue decreasing over three years.
Q1 FY 2026 showed strong U.S. growth, with subdued performance in other regions due to stock shortages and lower marketing spend.
Latest events from Bubs Australia
- FY26 revenue guidance raised to $120–125M with double-digit growth and strong EBITDA outlook.BUB
Status update26 Mar 2026 - Revenue up 14% to $55.5M, led by US growth; gross margin 48%; FY26 outlook upgraded.BUB
H1 202627 Feb 2026 - Revenue up 34% to $80m, with strong US/China growth and positive FY2025 outlook.BUB
H2 202423 Jan 2026 - Strong growth, margin gains, and US/China expansion set up for FY25 profitability.BUB
AGM 202413 Jan 2026 - Net profit of AUD 3.6M and 23% revenue growth, but FDA and funding risks remain.BUB
H1 20253 Dec 2025 - Revenue up 29% to $102.5M, USA leads growth, positive EBITDA, and FDA submission for US access.BUB
H2 202523 Nov 2025 - Net revenue up 30% to $25.6m, EBITDA positive, and $22.9m in liquidity at quarter end.BUB
Q1 2026 TU30 Oct 2025 - FY25 saw 29% revenue growth, positive EBITDA, and strong US and China market performance.BUB
Q4 2025 TU28 Jul 2025